- POSITIVE
Quarterly Revenue Mukka Proteins Jun-2026 Quarterly Revenue is Rs 408 Cr which is growth of 193.4% YoY.
- POSITIVE
Quarterly Net Profit Mukka Proteins Jun-2026 Quarterly Net Profit is Rs 19 Cr which is growth of 1104.7% YoY.
Mukka Proteins Live Share Price Today, Share Analysis and Chart
NSE 02 Nov, 2026 3:31 PM (IST)
Mukka Proteins Stock Price Analysis
Day Price Range-0.8% 1 Day return | 24.2 (LTP) 23.824.8 LowHigh |
|---|---|
Week Price Range-1.8% 1 Week return | 24.2 (LTP) 23.725.1 LowHigh |
Month Price Range-6.0% 1 Month return | 24.2 (LTP) 2330.2 LowHigh |
52 Week Price Range-4.0% 1 Year return | 24.2 (LTP) 18.333.3 LowHigh |
Mukka Proteins quarterly results: revenue, profit, and P&L – 13 quarter history
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 408.2 | 326.7 | 563.9 | 227.9 | 139.1 | 329.6 | 293.2 | 129 | 151.5 | 235 | 492.1 | 321 | 240.6 | ||
Operating Exp. | 364 | 283.8 | 525.6 | 208.4 | 125.1 | 302 | 250.3 | 119 | 140.4 | 208.2 | 472 | 280.8 | 226.1 | |
Operating Profit | 41.8 | 29.1 | 32.7 | 13.9 | 10.7 | 23.3 | 36.7 | 7.1 | 8 | 22.6 | 11.6 | 34.2 | 13.1 | |
Operating Profit Margin % | 10.31% | 9.31% | 5.85% | 6.26% | 7.85% | 7.15% | 12.77% | 5.66% | 5.40% | 9.78% | 2.40% | 10.85% | 5.47% | |
Depr. | 2 | 2.6 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | 1.6 | 1.5 | 1.5 | 1.4 | 1.4 | 1.3 | |
Interest | 14.7 | 13.7 | 13.7 | 12.1 | 10.4 | 8.9 | 10.1 | 7.9 | 7.4 | 7.5 | 5.4 | 5.9 | 5.4 | |
Profit Before Tax | 27.5 | 26.6 | 24.6 | 5.8 | 2.3 | 17.1 | 31.7 | 1.7 | 2.1 | 17.9 | 13.2 | 32.9 | 7.7 | |
Tax | 8.1 | 7.7 | 5.8 | 2.2 | 0.7 | 4 | 6.6 | -0.5 | 0.8 | -4.5 | 4.2 | 5.9 | 3.3 | |
Net Profit | 19.4 | 18.9 | 18.8 | 3.6 | 1.6 | 13.1 | 25.1 | 2.2 | 1.3 | 22.3 | 9.1 | 27 | 4.4 | |
EPS Adj. latest | 0.7 | 0.6 | 0.6 | 0.1 | 0.1 | 0.4 | 0.8 | 0.1 | 0 | 0.7 | 0.3 | 0.9 | 0.2 | |
Net profit TTM | 60.7 | 42.9 | 37.1 | 43.4 | 42 | 41.7 | 50.9 | 34.9 | 59.7 | 62.8 | 62.9 | 70 | - | |
Basic EPS TTM | 2 | 1.4 | 1.2 | 1.5 | 1.4 | 1.4 | 1.7 | 1.2 | 2 | 2.1 | 629.1 | 3.2 | - | |
Earnings Transcripts | ||||||||||||||
Results PDF | ||||||||||||||
Result Notes |
Mukka Proteins Technical Analysis
Mukka Proteins EMA & SMA
| 5 Day | 24.5 |
|---|---|
| 10 Day | 25 |
| 12 Day | 25.2 |
| 20 Day | 25.7 |
| 26 Day | 26.0 |
|---|---|
| 50 Day | 26.2 |
| 100 Day | 25.7 |
| 200 Day | 25.5 |
Mukka Proteins Delivery And Volume
Mukka Proteins Resistance and Support
| First Resistance | 24.7 |
|---|---|
| Second Resistance | 25.2 |
| Third Resistance | 25.7 |
| First Support | 23.7 |
|---|---|
| Second Support | 23.3 |
| Third Support | 22.8 |
| Day RSI | 38.2 |
|---|---|
| Day MACD | -0.8 |
| Day MFI | 53 |
| Day MACD Signal Line | -0.6 |
Mukka Proteins Beta
| 1 Month | 1.1 |
|---|---|
| 1 Year | 1.1 |
| 3 Month | 0.9 |
|---|---|
| 3 Year | - |
Mukka Proteins Price Change Analysis
Mukka Proteins Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| HRTI PRIVATE LIMITED | Bulk | Sell | 16 Jul 2024 | 53.16 | 4,423,136 | NSE |
| YUGA STOCKS AND COMMODITIES PRIVATE LIMITED . | Bulk | Sell | 16 Jul 2024 | 54.06 | 1,984,995 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | Bulk | Sell | 16 Jul 2024 | 53.04 | 2,950,216 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 16 Jul 2024 | 53.62 | 2,407,387 | NSE |
| DIPAN MEHTA COMMODITIES PRIVATE LIMITED | Bulk | Sell | 16 Jul 2024 | 53.93 | 1,668,985 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | Bulk | Purchase | 16 Jul 2024 | 52.96 | 2,950,216 | NSE |
| HRTI PRIVATE LIMITED | Bulk | Purchase | 16 Jul 2024 | 53.14 | 4,505,648 | NSE |
| DIPAN MEHTA COMMODITIES PRIVATE LIMITED | Bulk | Purchase | 16 Jul 2024 | 54.24 | 1,768,489 | NSE |
| YUGA STOCKS AND COMMODITIES PRIVATE LIMITED . | Bulk | Purchase | 16 Jul 2024 | 56.06 | 1,984,995 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Purchase | 16 Jul 2024 | 53.59 | 2,407,387 | NSE |
Mukka Proteins Corporate Actions
Mukka Proteins Board Meetings
Mukka Proteins past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
112 Aug 2026 | Quarterly Results | - |
212 Jun 2026 | To consider Funds Raising & Others | To consider other business matters. |
315 May 2026 | Audited Results & Raising of funds | - |
412 Feb 2026 | Quarterly Results | (Revised) |
512 Nov 2025 | Quarterly Results | - |
Mukka Proteins Research Reports
Mukka Proteins research reports with share price targets, and buy/hold/sell recommendations from top brokers.
Mukka Proteins Corporate Filings
Mukka Proteins BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 02 Nov 2026 | Mukka Proteins Ltd - 544135 - Board Meeting Intimation for Consider And Approve The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30Th September 2026 | Mukka Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended 30th September 2026 | |
| 27 Oct 2026 | Mukka Proteins Ltd - 544135 - Intimation Of US FDA Registration. | Intimation of US FDA Registration. | |
| 09 Oct 2026 | Mukka Proteins Ltd - 544135 - Intimation Of Commencement Of Commercial Production By Overseas Subsidiary. | Intimation of commencement of commercial production by overseas subsidiary. | |
| 09 Oct 2026 | Mukka Proteins Ltd - 544135 - Intimation Of Giving Corporate Guarantee And Security By The Company. | Intimation of giving corporate guarantee and security by the Company. | |
| 07 Oct 2026 | Mukka Proteins Ltd - 544135 - Announcement under Regulation 30 (LODR)-Credit Rating | Intimation of Credit Rating. |
Mukka Proteins Documents
Mukka Proteins Annual Reports
Mukka Proteins financials, including annual results, balance sheets, and cash flow statements.
Mukka Proteins Credit Ratings
Mukka Proteins credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 06 Oct 2026 | care ratings | Mukka Proteins Limited | Link | |
| 25 May 2026 | care ratings | Mukka Proteins Limited | Link | |
| 07 Jan 2026 | care ratings | Mukka Proteins Limited | Link | |
| 29 Jan 2025 | icra ratings | Mukka Proteins Limited | Ratings withdrawn | Link |
| 14 Jan 2025 | care ratings | Mukka Proteins Limited | Link |
Mukka Proteins Investor Presentations
Mukka Proteins investor presentations, including business updates, financial insights, and strategic initiatives.
Mukka Proteins - Company Profile
Mukka Proteins Management Structure
Mukka Proteins management structure with salaries, total experience, and qualifications.
Mukka Proteins Board of Directors
Mukka Proteins Board of directors with salaries, total experience, and qualifications.
About the company - Business Profile
Mukka Proteins Ltd. (MUKKA) is a key player in the Indian marine protein industry, specializing in the manufacture and export of fishmeal, fish oil, and fish-soluble paste. With an estimated 25%–30% market share in the Indian fishmeal and fish oil segment, the company serves as a vital supplier to the aquaculture, poultry, and livestock industries globally. Mukka Proteins has also expanded into alternate proteins through insect-based products and entered the frozen seafood sector, positioning itself as an integrated animal protein and sustainability platform.
Key Points
- Key Facts: Founded in 1977 as a partner firm and incorporated in its current form in 2010, the company is headquartered in Mangaluru, Karnataka. It listed on the NSE and BSE on March 7, 2024. The company is promoter-led, with Mr. Kalandan Mohammed Haris serving as Managing Director and CEO.
- Operations and Resources: The company operates multiple manufacturing facilities, including two units in Karnataka (Mangaluru and Ullal) and a presence in Gujarat. Internationally, it has established units in Oman. Its total installed capacity for fishmeal, fish oil, and paste stands at 2,64,390 MT per year.
- Market and Significance: Mukka Proteins exports to over 25 countries, including China, Chile, Saudi Arabia, and South Korea. Its products are essential high-protein ingredients for aq꿮d (shrimp and fish) and poultry feed. It is one of the few Indian companies to commercialize insect protein (insect meal and oil).
- Sustainability and Innovation: The company focuses on waste-to-value solutions, utilizing fish by-products to produce nutrient-rich feed. It has a dedicated R&D effort for nutritional quality enhancement and has secured a significant order of ₹474.89 crore for the treatment of legacy leachate, reflecting its diversification into environmental services.
Business Model and Segment Performance Mukka Proteins follows an integrated business model that spans sourcing raw fish, processing it into high-protein ingredients, and global distribution. The company excels in large-scale steam-sterilized fishmeal production and has a first-mover advantage in the Indian insect protein market.
Revenue Breakdown (FY 2024-25 Annual Numbers):
- Standalone Revenue: ₹8,867.43 million (compared to ₹12,685.43 million in FY 2023-24).
- Consolidated Revenue: ₹10,064.16 million (compared to ₹13,798.29 million in FY 2023-24).
- Net Profit (Consolidated): ₹480.97 million for FY 2024-25.
- Geographical Reach: Exports contribute a significant portion of revenue, with a presence in over 25 countries across the Far East, Middle East, and South America.
Key Products and Technology:
- Fish Meal: High-protein ingredient for aquaculture and poultry.
- Fish Oil: Rich in Omega-3 fatty acids, used in aq꿮d, pharmaceuticals, and industrial applications.
- Insect Protein: Commercialized through subsidiary Ento Proteins Pvt Ltd, targeting alternate protein markets.
- Facility Advancement: Implementation of automated blending units and quality testing laboratories as per international standards (GMP+ B2 Certification).
Strategic Initiatives and Outlook:
- Acquisitions: Recently acquired GSM, FABBCO, Mukka Frozen, and MPL HRC Ecosolutions to strengthen its footprint.
- Consolidation: Plans to make Ento Proteins and HMPPL wholly-owned subsidiaries.
- Expansion: Approved capacity expansion in Bengaluru and strengthening of its carbon credit portfolio through Verra-listed projects.
- Future Outlook: Focus remains on expanding the product portfolio into higher-margin segments like frozen seafood and leveraging waste management contracts for steady cash flows.
References
